Introduction
Neutropenic sepsis is a well-known and life-threatening complication of bone marrow dysfunction and cytotoxic chemotherapy. Associated mortality rates range from 2 to 21% (Smith et al, 2006; Herbst et al, 2008) . Sepsis in general is a time-dependent medical emergency in which early, goal-directed resuscitation and the urgent administration of broad-spectrum antibiotics have proven benefits on outcome (Dellinger et al, 2008; Gaieski et al, 2010) .
A recent national investigation into avoidable patient deaths following chemotherapy identified serious short-comings in the management of neutropenic sepsis in the UK, including delayed administration of intravenous antibiotics (NCEPOD, 2008) . In F o r P e e r R e v i e w 2 response, the UK's National Chemotherapy Advisory Group published guidelines for improving the management of neutropenic sepsis (NCAG, 2009 ). These recommended a new "door-to-needle" time for antibiotic administration of one hour maximum, mirroring the international Surviving Sepsis Campaign's gold standard (Dellinger et al, 2008) . The National Institute for Clinical Excellence has since been commissioned to draft a national guideline for the prevention and best management of neutropenic sepsis.
Yet to date, neither the degree of regional variation in existing hospital guidelines for managing neutropenic sepsis, nor the extent to which local centres successfully meet their own standards, have been investigated at a national level. There are no national data on whether the one-hour target for neutropenic sepsis is being met, whether door-to-needle times vary significantly between hospitals (and, if so, why), or even whether speed of antibiotic delivery has a proven benefit for clinical outcome.
These questions are pertinent to all health professionals involved in acute hospital care. Evidence shows that much of the immediate assessment and treatment of patients presenting with neutropenic sepsis is delivered not by haematologists or oncologists, but by frontline emergency department staff and junior doctors on acute medical rotas (NCAG, 2009) . In other words, sub-optimal management of neutropenic sepsis is not a specialist concern so much as a practical imperative to be addressed by every hospital with acute facilities to which patients may present.
This paper aims to augment the existing evidence base by conducting the UK's first national audit of the immediate management of neutropenic sepsis in haematology patients. It seeks to identify:
1) the degree of regional heterogeneity in existing local management protocols, 2) the extent to which the one-hour door-to-needle target is being met nationally, 3) the potential barriers preventing the one-hour target from being translated into achievable practice, and concrete recommendations to overcome these.
Key questions include whether best practice may be identified and transferred and whether, in so doing, patient outcomes are modifiable. The collation and dissemination of local protocol and audit findings may act as a practical resource for hospital trusts, informing future policy and potentially improving clinical outcome.
Methods
MEDLINE and EMBASE were searched for English language papers, without date restriction, using the terms "neutropenic sepsis", "febrile neutropenia", "management", "treatment", "audit", "protocol", "guideline", "gold standard", "best practice" and their synonyms. All potentially relevant abstracts were retrieved and read in full.
All British Society for Haematology members were emailed a questionnaire regarding their unit's immediate management of patients presenting from the community with possible neutropenic sepsis. Their most up-to-date management protocols, policies or 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   3 guidelines, and any local audits investigating adherence to protocol were also requested. Respondents were contacted directly to clarify any uncertainties.
From the questionnaires and protocols, data were extracted on:
• definitions of fever and neutropenia • nature of any risk stratification • choice of first-line empirical antibiotics • use or not of prophylactic antibiotics • whether specific instructions were given:
(a) to be guided by clinical signs of sepsis, rather than temperature alone (b) not to wait for a full blood count before giving antibiotics (c) to administer the first dose of antibiotics within 1 hour (d) to write the first dose of antibiotics on the statim side of the drug chart (e) to contact the on-call haematology/oncology team regarding the patient From the audits, data were extracted on:
• time of presentation • location of presentation • symptoms on admission • time to first assessment • time to administration of first dose antibiotics ("door-to-needle time")
• effect of location of presentation on door-to-needle time
In addition, all specific reasons for delayed door-to-needle time -and all recommendations for overcoming these -identified in audits, protocols and completed questionnaires were collated.
We were unable to calculate p-values for the combined audit data, since all but one of the individual audits did not provide them, and only a small number of audits supplied individual patient data. Responses from 71 haematology departments were received. 10 of these were excluded since their data covered paediatric or non-UK centres. (Edit 1) Although the remaining 61 departments represent a relatively small proportion (28%) of the total number of haematology departments in the UK (n=220), respondents frequently supplied protocols and/or audits which covered multiple hospitals within a trust or region. Consequently, the data provided covered adult patients in 95 different hospitals across the UK (Table I) . Two thirds of these were district general hospitals; the rest tertiary referral centres. Their combined catchment area was just under 30 million people (over half the UK adult population).
Results

(Edit
100% of respondents stated that they had a written protocol governing their management of neutropenic sepsis, and 75% that they had audited their practice against these local standards. We received protocols from 90% of respondents and audits from 44% of them. The total number of patients audited was 627, with a median number of patients per audit of 22 (range 6-71). (Edit 2) It was not made clear whether the numbers of patients audited per centre was a reasonable representation of the incidence of neutropenic sepsis in each centre. The majority of the audits (89%) examined practice in 2008, 2009 or 2010 . Of the remainder, the least up-to-date audit occurred in 2006.
Definitions of "febrile" and "neutropenia" Definitions of "febrile" and "neutropenia" were extracted from each protocol provided (n=55). They demonstrated marked regional heterogeneity, with a total of ten different definitions recorded (Table II) .
"Neutropenia" was defined more consistently, with 67% of protocols using an absolute neutrophil count of <1·0 x 10 9 /l, 25% using <0·5 x 10 9 /l or <1·0 x 10 9 /l and expected to fall to <0·5 x 10 9 /l, and 8% using other values. One protocol did not define neutropenia numerically, instead providing a list of the types of patients likely to be at risk due to immunocompromise.
(Edit 7) Multiple definitions of "febrile" and "neutropenia" were also noted in the literature review, suggesting an international lack of consensus on how best to define neutropenic sepsis. The clinical usefulness of even the original diagnostic criteria for sepsis, severe sepsis and septic shock, which use a temperature of >38°C or <36°C (Bone et al, 1992) , has been increasingly questioned (Cohen et al, 2011) .
Risk stratification
15% of protocols (n=8) advocated classifying patients with potential neutropenic sepsis into low and high risk categories. Of these, four protocols recommended prescribing oral, as opposed to intravenous antibiotics to low-risk patients, as defined by the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index (Klaterskey et al, 2000) .
First-line empirical antibiotics
87% of protocols (n=48) recommended intravenous Tazocin and gentamicin as their firstline empirical antibiotics for patients thought to be neutropenic and septic. The remainder Prophylactic antibiotics 48% of respondents (n=29) confirmed in questionnaires that they prescribed prophylactic antibiotics to patients at risk of neutropenia. Oral ciprofloxacin was first line in all but two of these units.
Specific instructions given in protocols
Protocols were screened for any specific instructions relating to the immediate assessment and management of patients which might influence outcome. Four such instructions were identified, and their prevalence noted (Table III) .
In addition, respondents were asked in the questionnaire whether their unit recommended writing the first dose of antibiotics on the statim side of the drug chart, in order potentially to hasten their administration. 52% of units did so.
Time and location of initial presentation
Of the 27 audits received, 16 provided data on where patients initially presented (n=359). 59% of patients first presented to the emergency department (ED), to some form of acute medical assessment unit (MAU) or, rarely, to a high dependency unit (HDU). 41% presented directly to a specialist haematology or oncology ward.
Five audits (n=96) also documented the time of presentation. 50% of patients presented during core hours, defined as Monday -Friday, between 9am and 5pm. 50% presented out-of-hours, whether overnight or during weekends.
Symptoms on admission
Five audits noted patient signs and symptoms on presentation. Of these, three (n=82) documented patients' fever status. 70% of patients were febrile, 30% afebrile. One audit (n=71) noted that 15% of patients were asymptomatic on presentation, while 11% had a systolic blood pressure less than 90mm/Hg. In another small audit (n=6), 100% of patients had two or more signs of infection such as temperature, rigors or hypotension.
Time to first assessment 11 audits (n=137) described times to first nurse triage and/or to first doctor's assessment. The median times to triage ranged from 10 min to 1 h. The longest single time to triage noted was 3 h 8 min. The median times to first doctor's assessment ranged from 1 h 40 min to 2 h. The longest period before a doctor's assessment was 12 h 38 min.
Time to administration of first dose of antibiotics ("door-to-needle time") 25 of the 27 audits received (n=590) documented door-to-needle time for administration of first dose of intravenous antibiotics. Only 26% of patients received antibiotics within the target time of one hour. Median door-to-needle times (data from 16 audits) ranged from 55 min to 4 h (Fig 1) with only two audits demonstrating a median delay of under 1 F o r P e e r R e v i e w 6 hour. Delays of over 5 h were not uncommon, the longest being 21, 22 and 24 h respectively.
Effect of time and location of presentation on door-to-needle times
Six audits (n=104) examined whether where patients initially presented influenced speed of antibiotic delivery. In all six, the median door-to-needle time was longer when patients first presented to an ED/MAU rather than a Haematology/Oncology ward (Fig 2) . In one study, the median door-to-needle time was eight times as long in the ED/MAU as it was on the day ward (4 h v 30 min).
Two audits (n=35) evaluated the impact of time of presentation on door-to-needle times. In both, core-hours were defined as 9am-5pm, Monday to Friday; out-of-hours as weekends and weekday evenings/nights. The two median door-to-needle times for corehours presentations were 2 h 25 min and 1 h 30 min. For out-of-hours presentations, these increased to 2 h 54 min and 3 h min respectively.
(Edit 3) The small sample sizes precluded analysis of the extent to which time and location of initial presentation independently influence door-to-needle times, or are instead variables which confound each other.
Patient outcomes
Four audits (n=149) provided data on deaths of audited patients. The combined mean mortality rate was 9%.
Specific reasons identified for delayed door to needle time, and practical recommendations for overcoming these Multiple different reasons for delayed door-to-needle times were identified in protocols, audits and completed questionnaires, such as antibiotics being prescribed in A&E but not given until transfer to a specialist ward, and doctors awaiting the full blood count before prescribing antibiotics. All such reasons are collated below (Table IV) , organised into the following four categories:
• lack of staff • lack of understanding of neutropenic sepsis • practical problems • communication issues between different members of staff/teams (Edit 4) The five most commonly cited reasons for delay, in order of frequency, were: 1) Antibiotics being prescribed by doctor but their administration delayed by nurse, or until patient was transfered to specialist ward (20% of all reasons cited) 2) Prolonged time to assessment by junior doctor (13%) 3) Lack of awareness of natural evolution of course of neutropenic sepsis, particularly how quickly an apparently well patient can deterioriate (10%) 4) Emergency departments not stocking the appropriate intravenous antibiotics (7%) All practical recommendations for improving door-to-needle times described in protocols, audits and completed questionnaires are also listed (Table V) . (Edit 5) 41% of audited departments (n=11) confirmed that the process of audit had led to improved doorto-needle times, citing the positive impact of specific innovations such as writing up antibiotics on the statim side of drug charts, ensuring emergency departments stocked appropriate antibiotics, and introducing patient-group directives for antibiotic prescription by nurses. The remaining audited departments made no mention of whether audit improved future performance.
Discussion
Although neutropenic sepsis is a common, costly and not infrequently fatal complication in haematology and oncology, it lacks clear, national, evidence-based guidelines informing urgency of antibiotic administration. In contrast, the immediate management of other lifethreatening, medical emergencies such as acute coronary syndrome and meningococcal sepsis tends to be deeply ingrained in everyday practice. For example, aspirin in the former and intramuscular antibiotics in the latter, have often been given before the patient even arrives in hospital.
One diagnostic challenge is that in immunosuppressed patients, the early presenting features of sepsis can be muted or even absent (de Naurois et al, 2010 ). Yet for other acute illnesses whose initial presentation is highly non-specific, such as meningococcal sepsis in infants, a culture of erring on the side of caution and treating empirically exists precisely to avoid delayed diagnoses and their potentially catastrophic consequences (Visintin et al, 2010) . Our audit highlights the fact that in the UK neutropenic sepsis lacks even consistency of definition, let alone treatment, with both "neutropenia" and "febrile" subject to multiple interpretations across different trusts and regions. As for national consensusbased therapy, the limitations of the current evidence base offer scant support for robust guidelines. For although the benefits of a one-hour door-to-needle time in septic shock and severe sepsis are underpinned by research (Dellinger et al, 2008; Gaieski et al 2010; Kumar et al 2006) , to the best of our knowledge no papers have examined its impact on neutropenic sepsis specifically, other than one small study of a two-hour target in intensive care unit patients, only half of whom were neutropenic (Larche et al, 2003) .
This study contributes to the evidence base by demonstrating that nationally, an aspirational door-to-needle time of one hour is far from being met in practice, with barely a quarter of audited patients receiving their antibiotics within this time. Our findings underscore the idea that late recognition of neutropenic sepsis might exacerbate delays, since in one local audit, nearly a third of patients were afebrile on presentation, while in another, 15% were asymptomatic. However, the fact that a small minority of hospitals (n=2) have managed to achieve the median target door-to-needle time suggests that such an aspiration is nonetheless achievable, and how these centres have achieved it demands further enquiry. Our audit data indicate that both the timing and the location of initial presentation may be relevant, since out-of-hours presentations and those to non-specialist admitting areas such as EDs or MAUs, show significantly increased door-to-needle times. Whether this relates primarily to greater staff-patient ratios, better understanding and awareness of neutropenic sepsis or increased familiarity with local protocol in specialist areas is not known. What is clear from the prolonged overall median times noted to first nurse triage (10 min -1 h) and to first doctor's assessment (1 h 40 min -2 h), is the current unfeasibility of improving compliance with the one-hour target.
In addition to staffing issues, local trusts have identified many other specific reasons for delay, with poor understanding of the natural history of neutropenic sepsis featuring prominently. This cannot be aided by local protocols described by respondents as inaccessible, hard to locate, or long and impenetrable to read. With this in mind, we screened all protocols received for clear, specific instructions which might promote shorter door-to-needle times, such as not waiting for a full blood count before giving antibiotics. The prevalence of the four such instructions identified (Table 3) ranged from 71% to only 39%. Perhaps unsurprisingly then, junior doctors were cited by respondents as contributing to delays by waiting for blood counts, renal function, senior review and haematology opinion before prescribing antibiotics.
More encouragingly, many respondents identified the act of audit itself as a factor in improving their own standards, a phenomenon mirrored in the literature (Amado et al, 2010) . In addition to re-writing protocols and educating staff, hospitals have responded to identified delays by introducing innovations as diverse as patient-held alert cards with a pre-signed first dose of antibiotics; neutropenic sepsis clerking documents to guide nurses/junior doctors with limited experience of such patients; and the opportunity for appropriately trained nurses to administer initial antibiotics without a doctor's prescription.
We hope that disseminating the full range of creative and practical responses to delayed door-to-needle times will promote debate as to what constitutes best practice and how best to achieve it. What is conspicuous by its absence is whether any of this has a tangible impact on patient outcomes. Without concrete data pertaining to neutropenic sepsis specifically, both the positive and negative putative effects of rapid, intravenous antibiotic therapy are at best speculative. It is conceivable, for example, that speed of fluid resuscitation is at least as important as door-to-needle time, yet there are currently no national targets for this aspect of immediate management. Other have called for a national clinical trial of best management of neutropenic sepsis (Richardson et al, 2008; Innes et al, 2005) , a recommendation which these audit findings serve only to reinforce.
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